PDS Biotechnology (NASDAQ:PDSB) Given Buy Rating at HC Wainwright

PDS Biotechnology (NASDAQ:PDSB)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $21.00 price objective on the stock.

A number of other equities analysts also recently commented on PDSB. StockNews.com downgraded shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, November 9th. Alliance Global Partners raised PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $12.33.

PDS Biotechnology Trading Down 10.7 %

NASDAQ PDSB opened at $2.01 on Friday. PDS Biotechnology has a 52 week low of $1.53 and a 52 week high of $6.85. The firm has a 50 day moving average of $3.21 and a two-hundred day moving average of $3.26. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $74.01 million, a PE ratio of -1.65 and a beta of 1.93.

Hedge Funds Weigh In On PDS Biotechnology

Several hedge funds have recently made changes to their positions in PDSB. Vanguard Group Inc. boosted its position in shares of PDS Biotechnology by 5.5% in the 1st quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock valued at $6,288,000 after purchasing an additional 82,135 shares during the period. Blair William & Co. IL lifted its stake in PDS Biotechnology by 204.4% in the second quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock valued at $357,000 after buying an additional 81,743 shares during the last quarter. Tempus Wealth Planning LLC acquired a new stake in shares of PDS Biotechnology in the second quarter valued at approximately $55,000. Cubist Systematic Strategies LLC purchased a new position in shares of PDS Biotechnology during the second quarter worth approximately $146,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of PDS Biotechnology in the 2nd quarter valued at $115,000. Hedge funds and other institutional investors own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.